Sakar Healthcare Limited announced its un-audited consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported a significant 62% year-on-year revenue growth for Q3FY26, reaching ₹7,034.2 lakhs (₹703.42 crore), driven by new market authorizations for oncology products and strong demand across the EU. EBITDA for the quarter increased by 58% YoY to ₹1,859.3 lakhs (₹185.93 crore), with EBITDA margins at 26%. Profit After Tax (PAT) saw a substantial jump of 126% YoY, reaching ₹1,024.9 lakhs (₹102.49 crore), resulting in a PAT margin of 15%. This improvement reflects operational leverage, enhanced efficiencies, and disciplined cost management. For the nine months ended December 31, 2025, revenue grew by 42% YoY to ₹18,063.9 lakhs (₹1,806.39 crore), and PAT increased by 66% YoY to ₹1,946.0 lakhs (₹194.60 crore). Business highlights include the completion of over 50 business contracts for oncology products, with over 40 discussions ongoing. Out of 211 dossiers shared globally, 102 have been submitted, and 11 have received Marketing Authorizations. The company's oncology facility has been approved as a manufacturing source for Accord Healthcare UK’s Imatinib supplies to the EU. Mr. Sanjay Shah, Managing Director, commented that Q3 has been a defining quarter with strong growth across key performance metrics. He added that FY27 is expected to be a year of acceleration with new approvals and increasing EU-linked supplies, reinforcing Sakar's commitment to becoming a globally trusted oncology partner.
